We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.07B
AUM Growth
+$214M
Cap. Flow
+$110M
Cap. Flow %
10.26%
Top 10 Hldgs %
29.29%
Holding
121
New
28
Increased
49
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$25.5M
2
RDUS
Radius Health, Inc.
RDUS
+$18M
3
LLY icon
Eli Lilly
LLY
+$16.4M
4
BHC icon
Bausch Health
BHC
+$16.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$12.9M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$30.2M
2
MRK icon
Merck
MRK
+$25.6M
3
STJ
St Jude Medical
STJ
+$21.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$18.6M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.22%
2 Financials 1.56%
3 Industrials 0.97%
4 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDT icon
1
Medtronic
MDT
$112B
$44.6M 4.17%
572,300
+22,300
+4% +$1.69M
ABBV icon
2
AbbVie
ABBV
$465B
$35.1M 3.29%
600,000
+20,000
+3% +$1.21M
MCK icon
3
McKesson
MCK
$104B
$33.7M 3.15%
149,000
+9,250
+7% +$2.05M
AGN
4
DELISTED
Allergan plc
AGN
$33.5M 3.13%
112,500
+24,500
+28% +$6.99M
HCA icon
5
HCA Healthcare
HCA
$90.6B
$31.8M 2.97%
422,500
+14,500
+4% +$1.04M
BHC icon
6
Bausch Health
BHC
$1.75B
$30.8M 2.88%
155,000
+91,750
+145% +$16.3M
PFE icon
7
Pfizer
PFE
$143B
$26.4M 2.47%
+801,040
New +$25.5M
AMGN icon
8
Amgen
AMGN
$209B
$26.2M 2.45%
164,000
+3,000
+2% +$472K
ACHC icon
9
Acadia Healthcare
ACHC
$2.52B
$26M 2.43%
362,500
+32,750
+10% +$2.1M
GILD icon
10
Gilead Sciences
GILD
$165B
$25M 2.34%
255,000
– –
PCYC
11
DELISTED
PHARMACYCLICS INC
PCYC
$22.5M 2.11%
88,000
-500
-0.6% -$96.5K
CELG
12
DELISTED
Celgene Corp
CELG
$22.4M 2.1%
194,500
+1,500
+0.8% +$179K
EVHC
13
DELISTED
Envision Healthcare Holdings Inc
EVHC
$21.9M 2.04%
190,380
+85,170
+81% +$9.26M
THOR
14
DELISTED
THORATEC CORPORATION
THOR
$21.6M 2.02%
515,000
-18,500
-3% -$706K
HUM icon
15
Humana
HUM
$43.9B
$19.1M 1.79%
107,500
+11,250
+12% +$1.78M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$18.8M 1.75%
108,250
+15,750
+17% +$2.85M
TMH
17
DELISTED
Team Health Holdings Inc
TMH
$18.2M 1.7%
311,000
+44,500
+17% +$2.52M
TRNX
18
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$17.3M 1.62%
660,000
+287,500
+77% +$7.28M
CVS icon
19
CVS Health
CVS
$135B
$16.9M 1.58%
164,000
+14,000
+9% +$1.42M
TVTX icon
20
Travere Therapeutics
TVTX
$5.17B
$16.8M 1.57%
+700,000
New +$10.7M
LLY icon
21
Eli Lilly
LLY
$1.08T
$16.7M 1.56%
+230,000
New +$16.4M
AET
22
DELISTED
Aetna Inc
AET
$16.7M 1.56%
156,500
+25,500
+19% +$2.5M
RDUS
23
DELISTED
Radius Health, Inc.
RDUS
$16.5M 1.54%
+400,000
New +$18M
CI icon
24
Cigna
CI
$78.4B
$15.8M 1.48%
122,000
+29,000
+31% +$3.37M
BIIB icon
25
Biogen
BIIB
$30.9B
$15.6M 1.46%
37,000
-8,500
-19% -$3.35M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $1.69B AUM
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Rock Springs Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rock Springs Capital Management held 121 positions worth $1.07B, up 25% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $110M of net new capital in Q1 2015, opening 28 new positions and adding to 49 existing holdings. Its largest new stake was Pfizer: 801,040 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $3.37M trimmed.

  • Rock Springs Capital Management's largest Q1 2015 buy was Pfizer: 801,040 shares worth $26.4M.
  • Rock Springs Capital Management added most to Bausch Health in Q1 2015, an estimated $16.3M increase.
  • Rock Springs Capital Management's biggest Q1 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $3.37M.
  • Rock Springs Capital Management fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $30.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.07B portfolio in Q1 2015.
  • Rock Springs Capital Management opened 28 new positions and closed 16 in Q1 2015.
  • Rock Springs Capital Management's portfolio value rose 25% quarter-over-quarter to $1.07B.

Based on Rock Springs Capital Management's 13F filing for Q1 2015, filed 15 May 2015.